Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Pioglitazone and metformin have both proven safe and efficacious in the treatment of type 2 diabetes. Their combination into a single tablet seems logical. This article reviews the data that are available for this combination. Because the tablets are not currently widely available, the review examines some aspects of the effects of both agents separately and in the few trials where they have been administered concurrently, though not as a single pharmaceutical preparation. Based on this evidence, the combination appears therapeutically efficacious and clinically safe. The side effects are not multiplicative and reflect those predictable from monotherapy with either agent.

Original publication

DOI

10.1358/dot.2007.43.7.1119722

Type

Journal article

Journal

Drugs Today (Barc)

Publication Date

07/2007

Volume

43

Pages

443 - 454

Keywords

Animals, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hypoglycemic Agents, Metformin, Pioglitazone, Therapeutic Equivalency, Thiazolidinediones